Outlook Therapeutics OTLK
NASDAQ OTLK
$0.56 +0.04 (+7.94%)
At close: Oct 21, 2026 · 4:00 PM EDT

Outlook Therapeutics (OTLK) EBIT Margin (2015 - 2025)

Updated

Outlook Therapeutics (OTLK) recorded EBIT Margin of -4744.25% in FY2025 (year ended Sep 30, 2025).

Analysis

Outlook Therapeutics (OTLK) EBIT Margin (2015 - 2025) Analysis & Trends

Starting with FY2015, Outlook Therapeutics' EBIT Margin history includes 6 fiscal years.

  • The FY2025 figure is the highest annual EBIT Margin in data going back to FY2015.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 51.16%
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 28.21%
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 37.86%
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn -3.52%
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn 32.97%
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 20.57%
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 34.95%
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn -133.21%
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 28.37%
10 Outlook Therapeutics 77.51 Mn 41.76 Mn -8,265.00 -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2025 -1,046.20%
Dec 31, 2024 -138,629.87%
Jun 30, 2024 -5,636.10%
Dec 31, 2023 -5,398.42%
Sep 30, 2023 -4,188.40%
Jun 30, 2023 -4,675.07%
Mar 31, 2023 -4,002.79%
Sep 30, 2021 -11,212.71%
Sep 30, 2019 -216.83%
Jun 30, 2019 -966.72%
Mar 31, 2019 -1,201.86%
Dec 31, 2018 -960.78%
Sep 30, 2018 -1,608.21%
Jun 30, 2018 -935.35%
Mar 31, 2018 -884.97%
Dec 31, 2017 -411.95%
Sep 30, 2017 -100.29%
Jun 30, 2017 -2,420.14%
Mar 31, 2017 -2,585.60%
Dec 31, 2016 -5,870.30%
API Access

Outlook Therapeutics EBIT Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebit-margin&ticker=OTLK&period=max&api_key=YOUR_API_KEY